FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295817676> ?p ?o ?g. }

• W4295817676 endingPage "S814" @default.
• W4295817676 startingPage "S814" @default.
• W4295817676 abstract "Retrospective evidence suggests that patients with high grade ovarian cancer (HGOC) progressing to PARP inhibitors (PARPi) might be less likely to response to platinum therapy. The aim of our study was to assess in preclinical models if trabectedin will be an active agent in carboplatin-and PARPi-resistant HGOC cell lines. HGOC Olaparib (OLA)/Carboplatin (carbo)-sensitive BRCA2 mutant p.Y1655* cell line PEO1, and carbo-resistant cell line PEO4 were acquired. PEO1 resistant to OLA (PEO1-R) cell line was generated by pulse method. Cells were exposed for 24 hours to the PEO1 IC75 OLA and recovered for two weeks. Pulses were repeated during a 6-month period. IC50 of OLA, carbo and trabectedin were calculated for PEO1, PEO4 and PEO1-R cell lines. DNA damage was assessed by gamma-H2AX expression by western-blot (WB). BRCA and TP53 mutations were explored by NGS. NGS confirmed that reversion of BRCA2 mutation was present in PEO4 but not in the PEO1-R cell line in which BRCA2 mutation p.Y1655* was detectable. TP53 mutations were invariable. We confirmed that PEO4 was platinum-resistant vs PEO1 parental line (IC50 for carbo 63.54uM vs 99.1uM; p<0.0001). Moreover PEO4 showed a cross-resistance to OLA (IC50 5.65 nM PEO1 vs 55.70 nM PEO4; p<0.0001). PEO1-R cell line was resistant to OLA compared with parental PEO1 (3.18 nM for PEO1 vs 48.31 nM PEO1R; p<0.0001) and PEO1-R showed a cross-resistance to carbo (42.47nM PEO1 s 71.05nM for PEO1R; p< 0.0001). In a second step we assessed if trabectedin could be a potential agent to overcome carbo or OLA resistance in cell lines. PEO4 carbo-resistant cell line was also resistant to trabectedin (trabectedin IC50 PEO1 378.7 nM vs PEO4 1231 nM; p=0.0021). However, OLA resistant PEO1-R cell line showed similar values for trabectedin IC50 compared to PEO1 (454nM vs 397nM for PEO1R; p=0.645). Increased gamma-H2AX expression in WB vs control was seen in all three lines PEO1, PEO1-R and PEO4 when treated with trabectedin. This preclinical in vitro model suggests that some HGOC cell lines resistant to PARPi could potentially be still sensitive to trabectedin." @default.
• W4295817676 created "2022-09-15" @default.
• W4295817676 creator A5001699241 @default.
• W4295817676 creator A5024239580 @default.
• W4295817676 creator A5025957294 @default.
• W4295817676 creator A5055580859 @default.
• W4295817676 creator A5074210806 @default.
• W4295817676 creator A5086647519 @default.
• W4295817676 creator A5087972087 @default.
• W4295817676 creator A5088510166 @default.
• W4295817676 creator A5091831331 @default.
• W4295817676 date "2022-09-01" @default.
• W4295817676 modified "2023-10-07" @default.
• W4295817676 title "585P Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines" @default.
• W4295817676 doi "https://doi.org/10.1016/j.annonc.2022.07.713" @default.
• W4295817676 hasPublicationYear "2022" @default.
• W4295817676 type Work @default.
• W4295817676 citedByCount "0" @default.
• W4295817676 crossrefType "journal-article" @default.
• W4295817676 hasAuthorship W4295817676A5001699241 @default.
• W4295817676 hasAuthorship W4295817676A5024239580 @default.
• W4295817676 hasAuthorship W4295817676A5025957294 @default.
• W4295817676 hasAuthorship W4295817676A5055580859 @default.
• W4295817676 hasAuthorship W4295817676A5074210806 @default.
• W4295817676 hasAuthorship W4295817676A5086647519 @default.
• W4295817676 hasAuthorship W4295817676A5087972087 @default.
• W4295817676 hasAuthorship W4295817676A5088510166 @default.
• W4295817676 hasAuthorship W4295817676A5091831331 @default.
• W4295817676 hasConcept C121608353 @default.
• W4295817676 hasConcept C126322002 @default.
• W4295817676 hasConcept C2776694085 @default.
• W4295817676 hasConcept C2778239845 @default.
• W4295817676 hasConcept C2780427987 @default.
• W4295817676 hasConcept C2781451048 @default.
• W4295817676 hasConcept C71924100 @default.
• W4295817676 hasConcept C98274493 @default.
• W4295817676 hasConceptScore W4295817676C121608353 @default.
• W4295817676 hasConceptScore W4295817676C126322002 @default.
• W4295817676 hasConceptScore W4295817676C2776694085 @default.
• W4295817676 hasConceptScore W4295817676C2778239845 @default.
• W4295817676 hasConceptScore W4295817676C2780427987 @default.
• W4295817676 hasConceptScore W4295817676C2781451048 @default.
• W4295817676 hasConceptScore W4295817676C71924100 @default.
• W4295817676 hasConceptScore W4295817676C98274493 @default.
• W4295817676 hasLocation W42958176761 @default.
• W4295817676 hasOpenAccess W4295817676 @default.
• W4295817676 hasPrimaryLocation W42958176761 @default.
• W4295817676 hasRelatedWork W196860179 @default.
• W4295817676 hasRelatedWork W2016371240 @default.
• W4295817676 hasRelatedWork W2028071082 @default.
• W4295817676 hasRelatedWork W2028488403 @default.
• W4295817676 hasRelatedWork W2081176690 @default.
• W4295817676 hasRelatedWork W2082847138 @default.
• W4295817676 hasRelatedWork W2089394671 @default.
• W4295817676 hasRelatedWork W2408800447 @default.
• W4295817676 hasRelatedWork W2419075599 @default.
• W4295817676 hasRelatedWork W2518969580 @default.
• W4295817676 hasVolume "33" @default.
• W4295817676 isParatext "false" @default.
• W4295817676 isRetracted "false" @default.
• W4295817676 workType "article" @default.